肿瘤细胞治疗研究
英文原题：CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities.
CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities.
中枢神经系统（CNS）肿瘤是儿童和青年癌症相关死亡的主要原因之一。
中枢神经系统（CNS）肿瘤是儿童和年轻成人癌症相关死亡的主要原因之一。尽管经过数十年的研究，这些肿瘤仍然缺乏有效的治疗方法，迫切需要新的治疗选择。虽然嵌合抗原受体（CAR）T细胞疗法已经彻底改变了血液系统恶性肿瘤的治疗，但这些细胞疗法在CNS肿瘤中才刚刚开始显示出活性证据。在这篇综述中，我们将讨论当前的CAR T细胞临床试验，重点关注儿童CNS肿瘤领域的试验。此外，我们将探索反向转化的力量——即应用从临床到实验室的临床研究见解来理解CAR T细胞在CNS肿瘤患者中成功或失败的机制。通过运用转化研究的完整循环，新型CAR T细胞疗法正在临床中进行测试，反向转化研究正在实验室中进行评估。综合这些数据，CNS CAR T细胞领域有望迭代改进CAR T细胞，以造福患有CNS肿瘤的儿童和年轻成人。
Central nervous system (CNS) tumors are one of the leading causes of cancer-related mortality in children and young adults. Despite decades of research, effective treatments for these tumors are still lacking and new therapeutic options are urgently needed. While chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of hematologic malignancies, these cellular therapies are only beginning to show evidence of activity in CNS tumors. In this review, we will discuss current CAR T cell clinical trials with a focus on trials in the pediatric CNS tumor space. In addition, we will explore the power of reverse translation-defined by applying clinical research insights from bedside-to-bench to understand the mechanisms of CAR T cell success or failure in patients-for CNS tumor CAR T cells. Employing the full cycle of translational research, novel CAR T cell therapies are being tested in the clinic and reverse translational studies are being assessed at the bench. Combining these data, the CNS CAR T cell field is poised to iteratively improve CAR T cells for children and young adults with CNS tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
